Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Current Leases: 2021-2025

Historic Current Leases for Avidity Biosciences (RNA) over the last 4 years, with Sep 2025 value amounting to $4.0 million.

  • Avidity Biosciences' Current Leases rose 4.28% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 4.28%. This contributed to the annual value of $3.8 million for FY2024, which is 5.63% up from last year.
  • As of Q3 2025, Avidity Biosciences' Current Leases stood at $4.0 million, which was up 1.07% from $3.9 million recorded in Q2 2025.
  • Avidity Biosciences' 5-year Current Leases high stood at $4.0 million for Q3 2025, and its period low was $1.8 million during Q4 2021.
  • Moreover, its 3-year median value for Current Leases was $3.8 million (2024), whereas its average is $3.7 million.
  • Data for Avidity Biosciences' Current Leases shows a peak YoY skyrocketed of 75.52% (in 2022) over the last 5 years.
  • Avidity Biosciences' Current Leases (Quarterly) stood at $1.8 million in 2021, then spiked by 75.52% to $3.1 million in 2022, then rose by 17.20% to $3.6 million in 2023, then increased by 5.63% to $3.8 million in 2024, then climbed by 4.28% to $4.0 million in 2025.
  • Its Current Leases stands at $4.0 million for Q3 2025, versus $3.9 million for Q2 2025 and $3.9 million for Q1 2025.